

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities.*



**AK MEDICAL HOLDINGS LIMITED**

**愛康醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1789)**

## **COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION FOR NEW SHARES UNDER GENERAL MANDATE**

**Placing Agent**  
**Goldman**  
**Sachs**

The Company is pleased to announce that completion of the Placing and the Subscription took place on 25 February 2020 and 4 March 2020, respectively. The Company received total net proceeds of approximately HK\$783.87 million from the Subscription and intends to use the same as general working capital of the Group, and, if any, future strategic investment.

Reference is made to the announcement of the Company dated 21 February 2020 (the “**Announcement**”) in relation to, among other things, the Placing and the Subscription. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

### **COMPLETION OF THE PLACING AND THE SUBSCRIPTION**

The Company is pleased to announce that completion of the Placing and the Subscription took place on 25 February 2020 and 4 March 2020, respectively.

All the conditions of the Placing have been fulfilled and completion of the Placing took place on 25 February 2020. A total of 53,500,000 Placing Shares have been successfully placed at the Placing Price of HK\$15.0 per Share to no fewer than six independent placees who and whose respective ultimate beneficial owners are independent of and not connected with the Company and its connected persons. None of the placees and their ultimate beneficial owners has become a substantial shareholder (as defined under the Listing Rules) of the Company upon taking up the Placing Shares.

Further, all the conditions of the Subscription have been fulfilled and completion of the Subscription took place on 4 March 2020. A total of 53,500,000 Subscription Shares (equal to the number of the Placing Shares successfully placed under the Placing) were subscribed by the Vendor at the Subscription Price of HK\$15.0 for each Subscription Share. The net share price for the Subscription (after the deduction of the expenses incurred by the Vendor (which, in turn, were borne by the Company) in relation to the Placing and the Subscription) is approximately HK\$14.65 for each Subscription Share. The Subscription Shares represent approximately 4.84% of the issued share capital of the Company as enlarged by the allotment and issue of the Subscription Shares.

The Company received total net proceeds of approximately HK\$783.87 million from the Subscription and intends to use the same as general working capital of the Group, and, if any, future strategic investment.

## EFFECT OF THE PLACING AND THE SUBSCRIPTION

The table<sup>(Note 1)</sup> below sets out the shareholding structure of the Company before and after the Placing and the Subscription, on the assumption that the placees do not hold any Shares other than the Placing Shares:

Shareholders	Immediately before Completion of the Placing and the Subscription		Immediately after Completion of the Placing but before Subscription		Immediately after Completion of the Placing and Subscription	
	Number of Shares	Approximate %	Number of Shares	Approximate %	Number of Shares	Approximate %
Vendor and parties acting in concert with (Note 2)	545,282,500	51.80	491,782,500	46.72	545,282,500	49.29
Other Directors (Not including Mr. Li and Ms. Zhang) (Note 3)	78,196,500	7.43	78,196,500	7.43	78,196,500	7.07
Placees	–	–	53,500,000	5.08	53,500,000	4.84
Other public shareholders	429,221,000	40.77	429,221,000	40.77	429,221,000	38.80
Total	1,052,700,000	100	1,052,700,000	100	1,106,200,000	100

### Notes:

1. This table does not take into account any Shares that may be issued pursuant to the exercise of any options granted under any existing share option schemes of the Company, during the relevant period or time above-mentioned.
2. The Vendor, which is wholly owned by Rainbow Holdings Limited, holds 535,157,500 Shares. Rainbow Holdings Limited is wholly owned by Trident Trust Company (HK) Limited, which is the trustee of LZY Trust. Mr. Li is the settlor of LZY Trust and can control how Trident Trust Company (HK) Limited, as the trustee of LZY Trust, exercises its discretion over LZY Trust. Accordingly, Mr. Li is deemed to be interested in the Vendor's interest in the Shares pursuant to the SFO. In addition, Ms. Zhang is deemed to be interested in 10,125,000 Shares held by Summer Limited, a company wholly owned by Ms. Zhang, and is the spouse of Mr. Li. Therefore, Ms. Zhang is deemed to be a party acting in concert with Mr. Li pursuant to the Takeovers Code.

3. The 78,196,500 Shares are held by two Directors. 65,818,500 Shares are held by Suntop Limited, a company wholly owned by Mr. Zhang Chaoyang, 12,285,000 Shares are held by Sanbao Limited, a company owned as to 30.22% by Ms. Zhao Xiaohong, and 93,000 Shares are directly held by Ms. Zhao Xiaohong.

By Order of the Board  
**AK Medical Holdings Limited**  
**Li Zhijiang**  
*Chairman*

Beijing, 4 March 2020

*As at the date of this announcement, the Board comprises Mr. Li Zhijiang, Ms. Zhang Bin, Mr. Zhang Chaoyang and Ms. Zhao Xiaohong as executive Directors, Mr. Li Wenming and Dr. Wang David Guowei as non-executive Directors, and Mr. Dang Gengting, Mr. Kong Chi Mo and Mr. Li Shu Wing David, as independent non-executive Directors.*